) empiric regimen, and time to adequate antibiotics on mortality. Adult patients admitted to the hospital with a positive CRKP respiratory culture and evidence of pneumonia were included. Patients were evaluated based on survival at 30 days. Results: This study evaluated 51 patients with CRKP pneumonia, of which, 19 (37.3%) were included in the nonsurvivor group and 32 (62.7%) were included in the survivor group. Baseline characteristics were similar, except patients in the nonsurvivor group were less likely to be male (42.1% vs. 71.8%, p=0.04), had a higher sequential organ failure assessment (SOFA) score (10 vs. 6.5, p<0.01), and were more likely to be intubated on the day the respiratory culture was taken (94.7% vs. 71.9%, p=0.04). There was no difference in the use of combination therapy (47.4% vs. 31.3%, p=0.25), tigecycline-based therapy (42.1% vs. 43.7% p=0.91), colistin-based therapy (21.0% vs. 9.4%, p=0.24), adequate empiric therapy (15.8% vs. 28.1%, p=0.31), or time to adequate antimicrobials (54 h vs. 64 h, p=0.49) between nonsurvivors and survivors, respectively. On multivariable analysis, SOFA score was found be an independent predictor of 30-day mortality (odds ratio 1.27, 95% confidence interval 1.07-1.61, p<0.01). Conclusions: In patients receiving treatment for CRKP pneumonia, the use of combination therapy was not significantly associated with 30-day mortality.
ASSOCIATION BETWEEN PRE-OPERATIVE CEFAZOLIN DOSE AND SURGICAL SITE INFECTION IN OBESE PATIENTS
William Peppard, David Eberle, Danielle Mabrey, John Weigelt Learning Objectives: Obesity in the U.S. has increased in incidence and is a well-known risk factor for surgical site infections (SSIs). Taking pharmacokinetic properties into account, it is expected that higher doses of pre-operative cefazolin prophylaxis are required for obese patients. American Society of Health-System Pharmacists (ASHP) guidelines state that preoperatively, patients >80kg should receive 2g of cefazolin and patients >120kg should receive 3g. These are weak recommendations based off small, single-centered studies lacking clinical outcome data. In contrast, our institutional guidelines, implemented prior to the release of current ASHP guidelines, suggest using a 3g dose for patients ≥100kg. Methods: A retrospective, single center, observational study evaluated the incidence of SSIs in patients >100kg who received a preoperative cefazolin dose of either 2g or 3g. Primary outcome was the SSI rate, secondary included risk factors for SSIs, and the SSI rate in the subset of patients >120kg. Results: 439 patients were evaluated, 154 in the 2g group and 285 in the 3g group. Baseline demographics were similar between groups, exceptions being patients in the 3g group were more likely to be younger, admitted to the orthopedic service, weigh more, and be current or former smokers. Mean duration of follow-up for both groups was 77 days. Unadjusted SSI rates were 8.4% and 7.7% (OR 1.10, CI 0.54-2.25, p=0.79), for the 2g and 3g groups, respectively. When logistic regression was adjusted with propensity scores using 10 strata, and duration of follow-up was factored in, the groups still did not differ (OR 0.85, p=0.70) . The only variable associated with SSI was the use of implants/hardware, the rates of which were 50.5% and 79.4% for the non-SSI and SSI groups, respectively. Subset analysis yielded similar rates of SSI for ≥120kg and <120kg groups (6.9% and 8.6%, p=0.539). The dose of cefazolin was not associated with rate of SSI in either group. Conclusions: In otherwise similar obese surgical patients, the dose of pre-operative cefazolin (either 2g or 3g) is not associated with the rate of SSI.
DAILY BATHING WITH CHLORHEXIDINE GLUCONATE CLOTHS IMPROVES CLABSI RATES AND NURSE SATISFACTION
Jodi Mullen, Melissa Reynolds, Stephanie Oliveria, Joshua Campbell Learning Objectives: Central Line Associated Blood Stream Infection (CLABSI) rates increased following the opening of a new pediatric cardiovascular intensive care unit (PCICU) and the renovation of an adjacent PICU. Several improvement strategies were simultaneously executed. Daily bathing with a chlorhexidine gluconate (CHG) and water solution, which was already in policy, was practiced inconsistently. To improve compliance, pre-packaged CHG cloths were implemented for daily bathing. Methods: A multidisciplinary team, which included frontline staff, was formed to implement a robust CHG bathing strategy. Multi-modal education describing the rationale for CHG bathing, contraindications, bathing instructions, patient/family education, and references was developed. A Likert-type Nursing Bathing Practices survey to assess nurses' attitudes regarding CHG bathing was administered prior to the education sessions and repeated 2 mo later. During implementation, clinical leaders worked with staff and families to minimize barriers and ensure full adoption of the cloths. A 21-day challenge was designed as a friendly competition between the two units to determine which could be most compliant with daily bathing for 3 weeks. During this time, daily compliance rates were prominently displayed. Ongoing compliance with daily CHG bathing and monthly CLABSI rates was monitored. Results: CLABSI rates decreased after implementation of CHG bath cloths (8.9 vs. 0). Daily bathing compliance increased during the study period (55% vs. 92%). Nursing Bathing Practices survey results indicated a significant increase in nurse satisfaction with CHG bathing (3.74 vs. 4.78; p<0.01). Estimated average bathing time decreased by 46% (18.5 vs. 10 min; p<0.01). Conclusions: The incidence of CLABSI in PICU and PCICU patients decreased after implementation of prepackaged CHG bath cloths. The bath cloths were well-received and nurses indicated that bathing with the cloths was easier, had fewer barriers, and took less time. Compliance with daily CHG bathing was above the goal of 90% after bath cloth implementation.
EVALUATION OF A STANDARDIZED ANTIBIOTIC DESENSITIZATION PROTOCOL
Kelsey Aker, Gregory Peitz, Keith Olsen Learning Objectives: Antibiotic-induced IgE hypersensitivity reactions can result in potentially life-threatening complications.
Step-wise antibiotic desensitization is a process utilized to create a temporary period of drug tolerance in patients who acutely need specific antibiotic therapy. There is a paucity of published data that evaluates a uniform antibiotic desensitization process, particularly among various antibiotics in critically ill patients. Methods: A retrospective, observational chart review was performed to evaluate an antibiotic desensitization protocol utilized in the ICU at an academic medical center between September 1, 2012 and December 31, 2014. All patients included in the review underwent a step-wise standardized protocol while being monitored in the ICU. Potential cases were excluded if there was any deviation from the protocol. Patients who had undergone multiple cases of desensitization had each instance counted as separate events. The primary outcome of interest was the percentage of desensitization attempts that were successfully completed. Data regarding the safety of the desensitization process were evaluated, including: adverse reactions, the administration of rescue medications, and reason for any cessation of protocol. Results: A total of 23 unique desensitizations were undertaken in 13 patients. Twenty-two of the 23 (95.7%) cases of desensitization were successful. Adverse events were recorded in 7 of the 23 (30.4%) cases. The adverse events were generally mild in nature, with the most common being itching occurring in 6 cases (26.1%) and a rash or redness in 4 patients (17.4%). Rescue medications included diphenhydramine (7) and hydrocortisone (1) and were administered in response to these mild adverse events. The desensitization process had to be discontinued in one instance after a patient experienced bronchoconstriction. Conclusions: A step-wise standardized antibiotic desensitization protocol proved to be both effective and safe for many patients and may be a treatment option for individuals whose antibiotic choices are limited by IgE hypersensitivity.
EXCESS RISK OF ACUTE KIDNEY INJURY FROM LIPOSOMAL AMPHOTERICIN B AND IV CONTRAST CO-ADMINISTRATION?
John O'Horo, Omar Abu Saleh, Jasmine Marcelin, Douglas Osmon Learning Objectives: Acute kidney injury (AKI) is associated with poor short and long term outcomes in the critically ill. Patients with systemic mycoses are often evaluated with CT scans using intravenous (IV) contrast, and treated with liposomal amphotericin B. Each of these agents are independently associated with AKI, therefore we hypothesized that co-administration may result in an additional risk of AKI than either alone. Co-administration of nonsteroidal anti-inflammatories (NSAIDS) and IV contrast is associated with an 8% risk of AKI, and screening to prevent co-administration is currently recommended in Canadian Association of Radiologist guidelines. We sought to evaluate if co-administration of liposomal amphotericin B and IV contrast was a risk factor for AKI and thus should be
